- Research article
- Open Access
- Open Peer Review
Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions
© Xie et al; licensee BioMed Central Ltd. 2010
- Received: 10 January 2010
- Accepted: 28 October 2010
- Published: 28 October 2010
Circulating cell-free microRNAs have been identified as potential cancer biomarkers. However, the existence and the potential application of cell-free miRNAs in effusion samples are still uncertain. In order to explore the potential role of cell-free miRNA in malignant effusions, we selected 22 miRNAs differentially expressed in the serum of lung cancer patients and studied their expression levels in body cavity effusion samples.
We measured the expression of 22 miRNAs using qRT-PCR in two samples, which were pooled with 18 malignant and 12 benign effusions, respectively. After discarding 9 lowly expressed miRNAs, a panel of 13 miRNAs were measured in 29 samples (benign n = 11, malignant n = 18). We also carried out a WST-8 test to evaluate the docetaxel sensitivity of tumor cells directly isolated from 15 malignant effusions.
We compared the miRNA expression levels between benign and malignant effusions using a Mann-Whitney U test and found miR-24, miR-26a and miR-30d were expressed differently between the two groups (P = 0.006, 0.021 and 0.011, respectively). Cells isolated from effusions rich in cell-free miR-152 were more sensitive to docetaxel (r = 0.60, P = 0.016).
Collectively, our study demonstrated that cell-free miRNAs in the supernatant of effusions may aid in the diagnosis of malignancy and predict chemosensitivity to docetaxel.
- Lung Cancer Patient
- Primary Tumor Cell
- Malignant Effusion
- Chemosensitivity Test
Body cavity effusion is a clinical common manifestation and may cause dilemmas in treatment. Diagnosis of effusions is of particular importance for cancer patients and a co-existing malignant effusion implies an advanced stage of tumor and intricate clinical management. Currently, diagnosis of malignant effusions mainly relies on cytological analysis. However, the sensitivity is still limited to about 70% even with repeated analyses . Thus, alternative diagnostic methods are still in need to assist in the diagnosis of effusions. The supernatant of effusion samples may contain useful information in the form of proteins and nucleic acids. Tumor marker proteins , DNA methylation status  and cell-free mRNA levels  have been identified as potential biomarkers with limited improvement in diagnostic accuracy.
MicroRNAs (miRNAs) are a group of short RNAs that post-transcriptionally regulate expression of proteins by binding to the 3'UTRs of target mRNAs. miRNAs are involved in the development of cancer and specific miRNA expression profile may suggest not only the disease status but also the prognosis and response to chemotherapeutic reagents [5, 6]. Accumulating evidence suggested circulating cell-free miRNAs as potential biomarkers for disease status, such as liver injury , diabetes , myocardial infarction  and more importantly, cancer [8, 10]. Specific circulating miRNA profiles may act as novel biomarkers for cancer diagnosis and early detection. Thus, we hypothesized that malignant effusions may have a specific cell-free miRNA profile, which convey malignant information regarding the presence of tumor cells. We chose a panel of miRNAs that were deregulated in the serum of lung cancer patients and explored their possible role in malignant effusions. We also correlated the level of cell-free miRNA with sensitivity of tumor cells against docetaxel, a microtubule stabilizer widely used in cancer management.
Samples collection and Patients Information
Age < 60
Age < 60
Chemotherapeutic agent and chemosensitivity test
Primary tumor cells were prepared by Ficoll-Hypaque (specific gravity 1.077, Pharmacia) density centrifugation. The number and viability of cells were determined by cytological examination with trypan blue dye. The test drug concentration of docetaxel (DOC, donated by Jiangsu Hengrui Medicine Company, purity > 99.9%) was 12.4 μM, derived from pharmacokinetic data and adjusted for protein-binding to approximate the concentration achievable in the patient plasma. Cells were seeded in U-shape-96-well plates at 5× 104 cells/well and treated with drugs in triplicate for 72 h. WST-8 reagent (10 μl each) from Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) was added and absorbance was determined with a multiwell spectrophotometer (BioTek, VT, USA) at 460 nm. Inhibition rate = (1-absorbance of treated cells/control cells) ×100%. Only the specimens containing at least 50% cancer cells were enrolled for chemosensitivity test. And we have proved the increase of tumor cells number by the culture in our preliminary test. Serum free medium and polypropylene U-shape-96-well microplates can enrich tumor cells up to 80-90% .
Quantitative RT-PCR (qRT-PCR) analysis of miRNA expression
Samples for miRNA quantification were centrifuged at 8000 g for 20 min and the supernatants were collected. After adding 750 μl Trizol LS (Invitrogen, CA, USA) into 250 μl effusion samples, another 25 μl ath-miR156a (20 nM, synthesized by Takara, Japan) was supplemented into each sample tube. Total RNA was extracted using Trizol LS reagent (Invitrogen, CA, USA) according to the manufacture's instruction. The miRNA expression levels were quantified by real-time PCR using miRNA detection kit (Applied Biosystems, Foster city, CA, USA). Briefly, miRNAs were reverse-transcribed to cDNA with the AMV reverse transcriptase (Takara, Japan). Subsequently, real-time PCR was performed on Mx3000P cycler (Stratagene, USA). All reactions were run in triplicate. Ct data were determined using default threshold settings. The relative expression levels of miRNAs were calculated as 2-ΔΔCt , using ath-miR156a as reference and a mixture of RNA extracted from human lung cancer A549 cells and gastric cancer BGC-823 cells (1:1) as the calibrator.
Mann-Whitney U test was used to compare the expression of each miRNA between malignant and benign groups. Spearman correlation coefficient was used to analyze the relationship between miRNA levels and inhibition rates of docetaxel on tumor cells. All these statistics were done by a statistics program, SPSS version 13.1 (SPSS Inc, Chicago, IL, USA). A P value < 0.05 (two tailed) was considered statistically significant.
The stability of miRNAs in the effusion samples
Expression levels of cell-free miRNAs in malignant and benign effusion samples
Initial evaluation of expression levels for 22 miRNAs.
Cell-free miRNAs in effusion samples may predict cell sensitivity against docetaxel
In the current study, we explored the expression of cell-free miRNAs in malignant effusion samples, and found that malignant effusions have higher expression levels of miR-24, miR-26a and miR-30d. This suggests that malignant effusions may have a different cell-free miRNA expression profile. miR-24, miR-26a and miR-30d are differentially expressed in a panel of cancers [14–17]. Chen et al  demonstrated that these three miRNAs were highly expressed in the serum of lung cancer patients compared to healthy control. Our result is in accordance with the result in the serum of lung cancer patients.
This study also revealed that effusion samples with tumor cells resistant to docetaxel contain lower levels of cell-free miR-152 than those from chemo-sensitive tumor cells. We demonstrated for the first time that cell-free miRNAs may be potential diagnostic biomarkers for diagnosis and drug sensitivity.
Currently used biomarkers mainly rely on tumor specific peptides derived from proteomic profiling . However, as tumor-associated proteins constitute only a minor fraction compared with normal proteins, the sensitivity for these "tumor proteins" may be limited. Cell-free nucleic acids have recently attracted interest as the diagnostic biomarkers for cancer. Several studies have focused on cell-free nucleic acids from fluid samples and explored their potential application as diagnostic biomarkers , . Up to now, cell-free miRNAs have been studied well in plasma, serum, urine , saliva  and sputum . Recently published reports proved that cell-free miRNAs in plasma or serum are stable and can be used to distinguish cancer patients from healthy subjects [8, 10, 23]. In view of the success of cell-free miRNAs of other body fluids in cancer diagnosis and the results of this study, cell-free miRNAs may serve as novel diagnostic biomarkers in the diagnosis of body cavity effusions with minimal invasiveness and sample requirement.
Docetaxel is a tubulin-binding agent that induces cell death through stabilizing microtubules after binding to β-tubulin. Interogation of miRGen, a web tool for miRNA target prediction and function , revealed a group of microtubule related genes that may be potential targets of miR-152, including β- tubulin2b, β-tubulin 4q-chain, β-tubulin 6 and β-tubulin 8. A group of ATP-binding cassettes (ABC) transporters was also identified as potential targets of miR-152, including ABCA1, ABCB7 and ABCD3. Chemotherapeutic resistance of tumor cells may be due to the drug pumps, which are mainly made up of ABC proteins . These two types of possible targets may explain partly the reason for lower expression of cell-free miR-152 in docetaxel resistant group. However, data is still scarce and further research is needed.
In summary, we showed that malignant effusion supernatant had a different profile of miRNAs when compared to benign samples. The expression levels of cell-free miR-152 may discriminate docetaxel sensitive samples from resistant samples. Given the results from this study, additional potential markers may be revealed by more systematic miRNA profiling in the future.
This research was supported by National Natural Science Foundation of China (30872471), Science and Technology Development Plan of Nanjing (200801078) and the Scientific Research Foundation of Graduate School of Nanjing University (2007CL04).
- Lee JH, Hong YS, Ryu JS, Chang JH: p53 and FHIT mutations and microsatellite alterations in malignancy-associated pleural effusion. Lung Cancer-J Iaslc. 2004, 44: 33-42. 10.1016/j.lungcan.2003.10.007.View ArticleGoogle Scholar
- Topolcan O, Holubec L, Polivkova V, Svobodova S, Pesek M, Treska V, Safranek J, Hajek T, Bartunek L, Rousarova M, Finek J: Tumor markers in pleural effusions. Anticancer Res. 2007, 27: 1921-1924.PubMedGoogle Scholar
- Katayama H, Hiraki A, Aoe K, Fujiwara K, Matsuo K, Maeda T, Murakami T, Toyooka S, Sugi K, Ueoka H, Tanimoto M: Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion. Int J Cancer. 2007, 120: 2191-2195. 10.1002/ijc.22576.View ArticlePubMedGoogle Scholar
- Wang T, Qian X, Wang Z, Wang L, Yu L, Ding Y, Liu B: Detection of cell-free BIRC5 mRNA in effusions and its potential diagnostic value for differentiating malignant and benign effusions. Int J Cancer. 2009, 125: 1921-1925. 10.1002/ijc.24516.View ArticlePubMedGoogle Scholar
- Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 2006, 6: 857-866. 10.1038/nrc1997.View ArticlePubMedGoogle Scholar
- Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW: MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009, 361: 1437-1447. 10.1056/NEJMoa0901282.View ArticlePubMedPubMed CentralGoogle Scholar
- Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, Johnson JM, Sina JF, Fare TL, Sistare FD, Glaab WE: Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem. 2009, 55: 1977-1983. 10.1373/clinchem.2009.131797.View ArticlePubMedGoogle Scholar
- Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18: 997-1006. 10.1038/cr.2008.282.View ArticlePubMedGoogle Scholar
- Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, Li K, Yu B, Li Z, Wang R, Wang L, Li Q, Wang N, Shan H, Li Z, Yang B: Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun. 2010, 391: 73-77. 10.1016/j.bbrc.2009.11.005.View ArticlePubMedGoogle Scholar
- Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008, 105: 10513-10518. 10.1073/pnas.0804549105.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T, Liu B: ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. Bmc Cancer. 2008, 8: 97-10.1186/1471-2407-8-97.View ArticlePubMedPubMed CentralGoogle Scholar
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.View ArticlePubMedGoogle Scholar
- Liu B, Wang T, Qian X, Liu G, Yu L, Ding Y: Anticancer effect of tetrandrine on primary cancer cells isolated from ascites and pleural fluids. Cancer Lett. 2008, 268: 166-175. 10.1016/j.canlet.2008.03.059.View ArticlePubMedGoogle Scholar
- Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006, 103: 2257-2261. 10.1073/pnas.0510565103.View ArticlePubMedPubMed CentralGoogle Scholar
- Marton S, Garcia MR, Robello C, Persson H, Trajtenberg F, Pritsch O, Rovira C, Naya H, Dighiero G, Cayota A: Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia. 2008, 22: 330-338. 10.1038/sj.leu.2405022.View ArticlePubMedGoogle Scholar
- Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, Liu CG, Petrocca F, Troncone G, Calin GA, Scarpa A, Colato C, Tallini G, Santoro M, Croce CM, Fusco A: Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene. 2007, 26: 7590-7595. 10.1038/sj.onc.1210564.View ArticlePubMedGoogle Scholar
- Lu Y, Ryan SL, Elliott DJ, Bignell GR, Futreal PA, Ellison DW, Bailey S, Clifford SC: Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma. PLoS One. 2009, 4: e6159-10.1371/journal.pone.0006159.View ArticlePubMedPubMed CentralGoogle Scholar
- Kuralay F, Tokgoz Z, Comlekci A: Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin. Clin Chim Acta. 2000, 300: 43-55. 10.1016/S0009-8981(00)00302-8.View ArticlePubMedGoogle Scholar
- Salani R, Davidson B, Fiegl M, Marth C, Müller-Holzner E, Gastl G, Huang HY, Hsiao JC, Lin HS, Wang TL, Lin BL, Shih IeM: Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions. Clin Cancer Res. 2007, 13: 5805-5809. 10.1158/1078-0432.CCR-07-0853.View ArticlePubMedGoogle Scholar
- Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, Warnecke JM, Sczakiel G: A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol.Google Scholar
- Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, Wong DT: Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009, 15: 5473-5477. 10.1158/1078-0432.CCR-09-0736.View ArticlePubMedPubMed CentralGoogle Scholar
- Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, Alattar M, Deepak J, Stass SA, Jiang F: Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer-J Iaslc. 2010, 67: 170-176. 10.1016/j.lungcan.2009.04.004.View ArticleGoogle Scholar
- Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ: Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009, 58: 1375-1381. 10.1136/gut.2008.167817.View ArticlePubMedGoogle Scholar
- Megraw M, Sethupathy P, Corda B, Hatzigeorgiou AG: miRGen: a database for the study of animal microRNA genomic organization and function. Nucleic Acids Res. 2007, 35: D149-D155. 10.1093/nar/gkl904.View ArticlePubMedGoogle Scholar
- Dean M: ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia. 2009, 14: 3-9. 10.1007/s10911-009-9109-9.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/591/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.